|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's range||129.33 - 130.75|
|52-week range||121.00 - 148.99|
|Beta (3Y monthly)||0.73|
|PE ratio (TTM)||21.51|
|Earnings date||15 Oct 2019|
|Forward dividend & yield||3.80 (2.91%)|
|1y target est||149.35|
The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.
Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.
Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.
Mallinckrodt's (MNK) shares gain as it agrees to sell its contract manufacturing unit to raise cash to settle liabilities from various opioid litigations.
Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.
Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.
How far off is Johnson & Johnson (NYSE:JNJ) from its intrinsic value? Using the most recent financial data, we'll take...
Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
Mallinckrodt (MNK) plunges as the risk of filing for bankruptcy rises ahead of the multi-district opioid litigation scheduled next month.
Johnson & Johnson (JNJ) receives European Commission's (EC) approval for the label expansion of Stelara for the treatment of adults with moderately-to-severely active ulcerative colitis (UC).
The fine issued to the company last week was the first of its kind relating to the opioid crisis, and its effects could be far-reaching.
U.S. District Judge Dan Polster, who oversees roughly 2,000 opioid lawsuits by states, counties and cities, said the plaintiffs can try to prove that drugmakers' deceptive marketing of the painkillers caused a harmful, massive increase in supply that pharmacies and distributors did not do enough to stop. "A factfinder could reasonably infer that these failures were a substantial factor in producing the alleged harm suffered by plaintiffs," the Cleveland-based judge wrote.
Bayer said it hired Johnson & Johnson executive Marianne De Backer to manage acquisitions and licensing deals at its drugs unit, as the German drugmaker turns to outside sources to boost its development pipeline. De Backer will take the role of Head of Business Development & Licensing at Bayer's pharmaceuticals division, joining from rival J&J, where she lead business development activities across different therapeutic areas and regions. Based in Berkeley, California, the Belgian national will have a more senior role than her predecessor, reporting directly to the head of pharmaceuticals, Stefan Oelrich, and taking a seat on the division's Executive Committee.
Allergan (AGN) settles with two counties of Ohio for $5 million related to the upcoming multidistrict litigation for opioid-based drug abuse.